Back to top
January 18, 2018
FDA Review: Clobazam Oral Soluble Film for Treating Lennox-Gastaut Syndrome
Research, Treatments

The U.S. Food and Drug Administration has accepted for review a New Drug Application for clobazam Oral Soluble Film (clobazam OSF) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older. The target date for completion of the FDA review is the third-quarter of 2018.
 
Clobazam OSF is administered using Aquestive's PharmFilm drug delivery technology. Similar in size and thickness to a stamp, Aquestive's PharmFilm dissolves instantly after being placed on the tongue and can be administered without water.

Two multicenter controlled studies were conducted to evaluate the bioequivalence of clobazam OSF with clobazam tablets, a benzodiazepine currently on market, at the same dosage strengths. Based on the studies, clobazam OSF was demonstrated to be bioequivalent to clobazam tablets and have comparable safety.

Learn More

 

Related News

February 21, 2018
GW Pharmaceuticals Announces That Pipeline Compound...

GW Pharmaceuticals announced that a Phase 2a proof-of-concept study of a pipeline compound GWP42006 in adult patients with focal seizures did...

February 20, 2018
News from Abroad: Xenon Pharmaceuticals Advances Second...

Xenon Pharmaceuticals Inc. announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901.

February 19, 2018
Maternal use of epilepsy drug may decrease school...

Pregnant women who used valproate had children with significantly lower school performance vs. children who were exposed to lamotrigine or not...